BioSpace News Archive

Vanda Pharmaceuticals Inc. reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 pneumonia in the ODYSSEY study.

• ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors • Clinical trial expected to enroll up to 24 patients across the U.S. SAN FRANCISCO and TAIPEI, Taiwan, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that it has dosed the first patient in its Phase 1 open-label, dose escalatio

Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™" or the “Company”) is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom extraction. Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s Licence, Mydecine™

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a global registry of patients with hypertrophic cardiomyopathy (HCM) focused on improving predictive measures of risk for complications and identifying biomarkers associated with adverse clinical outcomes.

Fully transparent, anti-fog masks available to help healthcare providers and essential workers to protect themselves, communicate better, and ease confusion “We are ready to join the fight against the current pandemic.” -- ALLYSA DITTMAR, PRESIDENT OF CLEARMASK [18-August-2020] BALTIMORE , Aug. 18, 2020 /PRNewswire/ -- ClearMask LLC, a privately he

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).

On Tuesday, August 18, 2020 Apotheka Systems Inc. announced they have launched their state of the art COVID-19 CRM platform to both their domestic and international clientele.

23 patients with second line Non-Small Cell Lung Cancer (NSCLC) participating in Stage 1, Part B Total of 87 patients out of up to 109 patients (80%) are enrolled and participating in the trial, with recruitment continuing for stage 2 of Part C at present Further data from TACTI-002 expected throughout calendar year 2020

Foldax® announced today that it has been selected as a finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma, produced by Questex.

Halberd Corp. Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19.